| Revenue Growth | Hospital revenue $6.8M (up 2% seq); Physician office $810k (down from $1.1M). |
|---|---|
| Mgmt Confidence | High conviction shown by CEO/COO $1M option exercise and salary-to-stock conversion. |
| Demand Visibility | Strongest hospital sales months in July/September; August impacted by systems transition. |
| Margin Trends | Gross margin fell to 56% from 61%; targeting 10-15 point improvement. |
| Op. Leverage | Plan to reduce annual cash operating expenses by $10M to $12M. |
| Pricing Power | Pressure from higher transfer pricing under BioTissue supply agreement through 2026. |
| Vol vs Price | Growth driven by deepening utilization; accounts buying 3+ lines rose 40%. |
| Segment Growth | Hospital channel is primary focus; physician office contributions expected to be minimal. |
| New Clients | Vendahy added to two largest U.S. GPO agreements in September. |
| Capex & Debt | $40M equity facility; $3M private placement; evaluating receivable-based credit facility. |
| Regulatory | In-house production start H1 2027 subject to process validation and regulatory requirements. |
| Commentary | Strategic shift from investment phase to 'disciplined expense management' and profitability. |
| New Launches | Catalyze 510k clearance received; VLU study top-line results expected early December. |
Growth
Hospital revenue grew 2% sequentially to $6.8M; total revenue fell to $7.6M from $7.9M.
Outlook
Raised FY2026 revenue floor to $28M-$29M; targeting 70% gross margins by FY2027.
Risks
Management pivoted on specific structural vs. non-recurring cost-saving breakdowns, citing the plan is still being finalized.
The company's earnings call, NASDAQ: BSEM, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
BioStem Technologies, Inc.: key numbers
- Share price
- $0.9601Close, Nov 16
- Market cap
- $18.4M
- Shares outstanding
- 19.18MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from BioStem Technologies, Inc.
All →BioStem Technologies Q3 2026 Results: Net Loss of $11.4M
BioStem Technologies reported a significant decline in revenue to $21.7 million for the nine months ended September 30, 2026, compared to $37.4 million in the prior year, resulting in a net loss from operations of $27.1 million. The company is facing liquidity challenges, including an unpaid $10 million clearance payment due to BioTissue and a substantial decrease in cash from $29.5 million to $971,145 over the nine-month period.
- Key figure
- Net loss $11.4M
BioStem Technologies Financial Results
BioStem Technologies reported Q3 2026 financial results, highlighting sequential hospital revenue growth to $6.8 million and increased customer penetration. The company raised its full-year 2026 revenue guidance and is finalizing a cost reduction plan to reduce annualized cash operating expenses by $10-$12 million.
- Term
- Q3 2026
“We grew hospital revenue again this quarter, and importantly, are doing so by adding new accounts and increasing penetration with existing customers. The number of customers buying two or more of our product lines grew 14% from the second quarter. We also completed the final step of our commercial infrastructure build-out, and with in-house production of Neox and Clarix expected to begin in the first half of 2027, we are on track to become a fully vertically integrated company with those product lines.”
Jason Matuszewski, Chair and CEO of BioStem
“With these foundations in place, we are focused on strengthening the balance sheet, raising our gross margin, reducing operating expenses and narrowing our adjusted EBITDA loss as we work toward breakeven.”
Jason Matuszewski, Chair and CEO of BioStem
BioStem Technologies Capital Raise of $3M
BioStem Technologies entered into a securities purchase agreement with institutional investors for a $3.0 million private placement of 735,296 shares of common stock. The offering includes Series A and Series B warrants to purchase additional shares at an exercise price of $3.83 per share, which could provide an additional $5.6 million if fully exercised. Proceeds are intended for working capital and general corporate purposes.
- Value
- $3M
- Counterparty
- institutional investors
BioStem Technologies Other 8-K Filing
BioStem Technologies entered into a $40 million committed equity facility with Roth Principal Investments, allowing the company to sell shares of common stock at its discretion over a 36-month period. The facility provides opportunistic access to capital for working capital and general corporate purposes, though no shares were sold at the time of the filing. Sales are subject to a registration statement being declared effective and a minimum threshold price of $1.00 per share.
- Counterparty
- Roth Principal Investments, LLC
- Term
- 36 months